<DOC>
	<DOCNO>NCT00413244</DOCNO>
	<brief_summary>The purpose study find give study drug , Androgel ( testosterone ) testosterone replacement help bring testosterone acceptable level find help improve heart condition male coronary artery disease ( CAD ) follow successful percutaneous coronary intervention .</brief_summary>
	<brief_title>The Cardiac Benefit Testosterone Replacement Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention Blockage Narrowed Heart Artery</brief_title>
	<detailed_description>Males coronary heart disease lower serum level bioavailable testosterone men similar age normal coronary angiogram ( English , European Heart Journal , 2000 ) . Low plasma testosterone associate know risk factor CHD , include age , obesity , hyperinsulinemia , diabetes , adverse lipid profile . Testosterone also show numerous study vasodilator . Recently , testosterone replacement compare placebo , hypogonadal men show improve time ischemic threshold , assess treadmill exercise test 4 12 week ( Malkin , Heart , 2000 ) . Prior study also show beneficial effect exercise-induced ischemia men CAD , exclusively hypogonadal men ( Jaffe , Br Heart J 1977 ; Rosano , Circulation , 1999 ; English , Circulation , 2000 ) . In addition , propose study would first study assess anti-anginal effect persists long term . This randomized , double-blind , placebo-controlled study evaluate safety efficacy testosterone supplementation hypogonadal men coronary artery disease follow successful revascularization percutaneous coronary intervention ( PCI ) . Only men successful coronary artery revascularization , stable cardiac medical regimen prior 4 week include . Eligible patient randomize 2:1 basis 50 subject receive 5 gram AndroGel 25 subject receive placebo gel . The men study demonstrate hypogonadism represent novel population demonstrate safety efficacy testosterone supplementation improve cardiac function outcome . We hypothesize treatment hypogonadism men CAD , follow successful PCI , significantly improve cardiac ischemic threshold assess cardiac stress test . Furthermore , additional cardiac endpoint angina status , endothelial function inflammatory serum marker also demonstrate significant benefit testosterone treat group .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Adult male patient coronary artery disease ( CAD ) ( one three vessel diseased ) . Stable cardiac status least 3 month percutaneous coronary intervention ( PCI ) . No change cardiac medication 4 week prior enrollment . Testosterone &lt; 300 ng/dl free testosterone &lt; 5.0 ng/dl bioavailable testosterone &lt; 150 ng/dl . Sex Hormone Binding Globulin ( SHBG ) &lt; 7nmol/liter Free Testosterone &lt; 50pg/dl Prostate Specific Antigen ( PSA ) &lt; 2.5 ng/mL 2.63.7ng/mL negative prostate biopsy within last 6 month pathology report available investigator 's review . Subgroup diabetic well moderately control diabetes ( define HgbA1c &lt; 9mg/dL . Hematocrit great 50 % . Severe hypertension ( exhibit systolic blood pressure &gt; 180mmHg diastolic blood pressure &gt; 110 mmHg baseline visit history malignant hypertension . Significant cardiac arrhythmia ( supraventricular tachycardia [ SVT ] ventricular tachycardia heart rate exceed 110 beat per minute Visit 1 ) . ECG abnormalities preclude ST segment analysis treadmill , inability walk treadmill . Poorly control , symptomatic , active medical problem ( HIV , hepatitis , cancer , benign prostatic hypertrophy , alcohol drug abuse , major depressive disorder ) . Neurological psychiatric disorder would compromise patient 's ability give inform consent adhere requirement protocol . History prostate cancer History hypersensitivity transdermal testosterone gel . International Prostate Symptom Score ( IPSS ) &gt; 19 Visit 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hypogonadal</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>percutaneous coronary intervention ( PCI )</keyword>
</DOC>